Effect of age on gastrointestinal and hepatic first-pass effects of levodopa in rats.
Presystemic elimination of levodopa (20 mg kg-1) has been studied in 5- to 104-week-old male Wistar rats. The gastrointestinal and hepatic contribution to the overall first-pass effect was estimated separately after the drug had been administered intravenously, orally and intraportally. The contribution of the gut to the overall first-pass effect of this drug was greater than that of the liver in any age-group of the rats. Both the overall and intestinal first-pass effects of levodopa were greatest in 11-week-old rats and relatively small in both young (between weeks 5 and 7) and aged (between weeks 52 and 104) rats. In contrast, the hepatic first-pass effect did not show any significant age-dependent change. Age-related change in the jejunal blood flow could not explain the unique age-dependence in the intestinal first-pass metabolism of levodopa. However, the present age-dependence in the oral systemic availability of this drug between adult (11 weeks) and aged (52 to 104 weeks) rats was found to be similar to the tendency that has been reported between normal adult subjects and aged patients with Parkinson's disease.
D000284:Administration, Oral; D000375:Aging / Q000502:physiology*; D000818:Animals; D001682:Biological Availability; D004064:Digestive System / Q000378:metabolism*; D005243:Feces / Q000032:analysis; D007267:Injections; D007275:Injections, Intravenous; D007583:Jejunum / Q000098:blood supply; D007700:Kinetics; D007980:Levodopa / Q000008:administration & dosage / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008102:Liver Circulation; D008297:Male; D011169:Portal Vein; D051381:Rats; D012039:Regional Blood Flow
D007980:Levodopa